Tiger Global Management Reduces $61M in Novo Nordisk A/S ($NVO)
Key Points
- Tiger Global Management changed its Novo Nordisk A/S ($NVO) stake by 100% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $NVO is Hold and an average price target of $47.13.
- $NVO last traded around $47.94.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Tiger Global Management reduced its position in Novo Nordisk A/S ($NVO), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Novo Nordisk A/S after selling 1,269,000 shares during the quarter.
Novo Nordisk A/S Stock Up 5.1%
Shares of Novo Nordisk A/S ($NVO) traded around $47.94 on Saturday, up 5.1% for the day.
Novo Nordisk A/S Earnings
Novo Nordisk A/S Dividend
Analysts Set New Price Targets
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Get Novo Nordisk A/S alerts
New 13F filings, insider trades, and analyst moves on $NVO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.